Table 2.
Data from patient self-report questionnaires
| A: Medication for tremor | |||
|---|---|---|---|
| Number of patients N = 26 |
Yes |
No |
Unknown |
| Preoperative |
12 (46) |
11 (42) |
3 (12) |
| Postoperative |
5 (19) |
16 (62) |
5 (19) |
| At follow-up |
9 (35) |
12 (46) |
5 (19) |
|
B: Patient self-report | |||
| |
All (N = 26) |
|
|
| VIM-DBS effect on tremor postoperative |
8.5 (0.1-10) |
|
|
| VIM-DBS effect on tremor at follow-up |
7.4 (0.1-10) |
|
|
| Overall satisfaction with VIM-DBS |
10 (0–10) |
|
|
|
C: Most common adverse effects with VIM-DBS | |||
| Variable |
All |
|
|
| Number of patients |
26 |
|
|
| Dysarthria |
17 (65) |
|
|
| Headache |
9 (35) |
|
|
| Parestesia |
6 (23) |
|
|
| Abnormal taste |
8 (31) |
|
|
| Dizziness |
5 (19) |
|
|
| Discomfort tongue |
4 (15) |
|
|
| Reduced balance or coordination |
4 (15) |
|
|
| Other | 8 (31) | ||
Patient self-report from follow-up questionnaire. Median follow-up 6.0 years (range, 2–16).
2A. Data are given in number of patients = n (%) reporting use of medication for tremor including betablockers, antiepileptics, benzodiazepines.
2B. VAS scale 1–10, where 0 is no effect of VIM-DBS on tremor and 10 is maximum effect.
2C. Data given in number of patients = n (%) experiencing adverse effects.